Colgate-Palmolive Company
CL
$90.66
+0.09%
Colgate-Palmolive Company is a global consumer goods leader operating in the Household & Personal Products industry, manufacturing and selling oral care, personal care, home care, and pet nutrition products under well-known brands like Colgate, Palmolive, and Hill's. The company is a dominant market leader in oral care globally and maintains a strong competitive position through its extensive international footprint, with about 70% of sales generated outside the U.S. The current investor narrative centers on the stock's performance as a defensive, high-quality staple amid market volatility, with recent attention on its ability to deliver stable growth and margins despite inflationary pressures, as evidenced by recent quarterly results showing revenue growth but a significant net income dip in Q4 2025.…
CL
Colgate-Palmolive Company
$90.66
Investment Opinion: Should I buy CL Today?
Rating & Thesis: Hold. CL is a high-quality, defensive staple with strong cash flow and a solid dividend, but its high leverage, low growth profile, and recent underperformance versus the market limit near-term upside, making it suitable for income-oriented, risk-averse portfolios but not for aggressive growth seekers. Analyst sentiment is generally positive but mixed, with several Buy ratings balanced by Hold stances from Barclays and Wells Fargo.
Supporting Evidence: The valuation is reasonable but not compelling, with a forward P/E of 22.13x and a Price-to-Sales ratio of 3.14x. Revenue growth is stable at 5.78% YoY, but this is modest. Underlying profitability is strong, with a Q4 operating margin of 20.6% and a TTM net margin of 10.46%. The company's immense free cash flow generation ($3.63B TTM) securely funds its 2.85% dividend yield. The stock trades roughly midway between its 52-week high ($99.33) and low ($74.55), suggesting a balanced risk/reward at current levels.
Risks & Conditions: The two biggest risks are 1) a further market rotation away from defensive stocks, prolonging underperformance, and 2) an inability to improve net income meaningfully post the Q4 charge, validating bearish concerns. This Hold rating would upgrade to a Buy if the forward P/E compresses below 20x or if the stock breaks above its 52-week high on sustained volume, signaling a new uptrend. It would downgrade to Sell if revenue growth decelerates below 3% or if the dividend payout ratio rises unsustainably above 95%. The stock is currently fairly valued relative to its own history and sector peers.
Sign up to view all
CL 12-Month Price Forecast
The outlook for CL is one of stability with limited near-term catalysts for significant outperformance. Its defensive profile is a double-edged sword: it offers protection in downturns but causes underperformance in rallies, as evidenced by its low beta and poor relative strength. The core business is healthy, with solid margins and cash flow, but the high debt and mature growth profile cap valuation expansion. The stance is neutral, as the stock appears fairly valued, trading between clear technical support and resistance. Confidence is medium due to the one-time Q4 charge clouding earnings visibility. The stance would turn bullish on a confirmed breakout above $99 with volume, or bearish on a breakdown below $85 coupled with margin deterioration.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Colgate-Palmolive Company's 12-month outlook, with a consensus price target around $117.86 and implied upside of +30.0% versus the current price.
Average Target
$117.86
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$73 - $118
Analyst target range
Analyst coverage for Colgate-Palmolive is robust, with the provided data showing five analysts providing estimates, though a full consensus recommendation and price target are not explicitly given in the dataset. The institutional ratings data from early 2026 shows a generally positive bias, with firms like Deutsche Bank (upgraded to Buy), Citigroup (Buy), JP Morgan (Overweight), B of A Securities (Buy), and Evercore ISI (Outperform) issuing favorable ratings, while Barclays and Wells Fargo maintain Equal Weight (Hold) stances. This distribution suggests a leaning towards a bullish consensus, with the majority of recent actions being Buy or Overweight recommendations. The range of analyst expectations is captured in the estimated EPS for the coming period, with a low of $4.72, an average of $4.84, and a high of $4.93. The tight range between the low and high estimates (a spread of only ~4.5%) indicates strong analyst conviction and low uncertainty regarding near-term earnings performance, which is typical for a stable, predictable company like Colgate. The high target likely assumes successful execution on pricing, market share gains, and margin stability, while the low target may factor in risks like input cost inflation or foreign exchange headwinds. The absence of explicit price targets in the data limits the calculation of implied upside, but the prevailing analyst sentiment, combined with the stock's defensive profile, suggests institutional support at current levels.
Bulls vs Bears: CL Investment Factors
The bull case for CL is anchored in its defensive characteristics, strong underlying cash generation, and reasonable valuation on a sales basis, supported by positive analyst sentiment. The bear case focuses on earnings volatility from a large one-time charge, high leverage, chronic market underperformance, and a low-growth profile. Currently, the bull side has stronger evidence, as the Q4 net loss appears isolated and the core business remains profitable and cash-generative. The single most important tension in the investment debate is whether the stock's defensive, low-beta nature and stable dividend will continue to attract capital in a market favoring growth, or if its high leverage and low growth will lead to further valuation compression and underperformance.
Bullish
- Strong Underlying Profitability & Cash Flow: Despite a one-time charge causing a Q4 net loss, the company's core operating income was $1.077 billion with a robust gross margin of 60.15%. The business generates massive free cash flow, with $3.634 billion TTM, supporting a high dividend payout ratio of 85.5% and providing financial flexibility.
- Defensive Profile with Low Beta: The stock's beta of 0.322 indicates it is roughly 68% less volatile than the market, making it a classic defensive holding. This characteristic is valuable during market downturns, as evidenced by its 14.18% gain over the last six months while the broader market rallied, suggesting a flight to safety.
- Analyst Sentiment Leaning Bullish: Recent institutional ratings from major firms like Deutsche Bank (Buy), Citigroup (Buy), and JP Morgan (Overweight) indicate positive analyst sentiment. The tight range of EPS estimates (low $4.72, high $4.93) reflects strong conviction in the company's stable earnings outlook.
- Resilient Revenue Growth & Market Leadership: Q4 2025 revenue grew 5.78% YoY to $5.23 billion, demonstrating resilience in a challenging environment. As the global oral care leader with a 70% international sales mix, the company benefits from diversified geographic exposure and entrenched brand equity.
Bearish
- Significant Earnings Volatility & One-Time Charge: Q4 2025 saw a dramatic swing to a net loss of -$37 million (EPS -$0.046) due to a $970 million 'other income expenses' charge. While likely non-recurring, it highlights financial reporting volatility and raises questions about underlying expense management.
- High Financial Leverage: The debt-to-equity ratio is elevated at 147.93, indicating significant financial leverage. While common in the sector, this increases interest expense sensitivity and could pressure cash flow if rates remain high, as seen with $64M in Q4 interest expense.
- Chronic Underperformance vs. Market: The stock has underperformed the S&P 500 significantly, with a -26.82% relative strength over the past year and -11.31% over three months. This suggests a lack of momentum and investor preference for growth over defensive names in the current cycle.
- Tight Liquidity & Low Current Ratio: The current ratio of 0.995 indicates the company has roughly equal current assets and liabilities, signaling tight liquidity. This leaves minimal buffer for operational hiccups and necessitates efficient working capital management.
CL Technical Analysis
The stock is in a volatile, range-bound consolidation phase with a slight positive bias over the observed six-month period. The price has advanced 14.18% over the last six months, yet it remains down 3.96% over the past year, indicating a recovery from lower levels but still underperforming its own 52-week high. Currently trading at $89.45, the stock sits approximately 56% of the way up from its 52-week low of $74.55 toward its high of $99.33, suggesting it is in the middle of its annual range, reflecting a balance between recovery potential and resistance near previous highs. The stock's beta of 0.322 confirms its defensive, low-volatility nature, being roughly 68% less volatile than the broader market, which is typical for a consumer staples giant. Recent momentum shows modest improvement but with notable volatility. The stock gained 1.80% over the past month and 0.69% over the past three months, indicating a tentative stabilization after a significant pullback from the February peak near $99. However, this short-term uptick pales in comparison to the S&P 500's 12% gain over three months, as reflected in a relative strength of -11.31%, highlighting significant underperformance against the market rally. The price action from the provided data shows a sharp rally from ~$77 in early January to ~$99 by late February, followed by a steep decline to ~$85 in March and a subsequent choppy recovery back to the ~$90 level, illustrating a lack of clear directional conviction. Key technical levels are clearly defined by the 52-week high of $99.33 and low of $74.55. A decisive breakout above the $99 resistance would signal a resumption of the prior uptrend and challenge all-time highs, while a breakdown below the $74.55 support would indicate a failure of the recovery and potentially open the door to further declines. The stock's low beta of 0.322 means its price movements are muted relative to the market, which reduces risk but also limits explosive upside potential; this characteristic makes it a suitable holding for risk-averse portfolios seeking stability over aggressive growth.
Beta
0.32
0.32x market volatility
Max Drawdown
-19.7%
Largest decline past year
52-Week Range
$75-$99
Price range past year
Annual Return
+0.6%
Cumulative gain past year
| Period | CL Return | S&P 500 |
|---|---|---|
| 1m | +2.9% | +1.5% |
| 3m | +3.6% | +13.4% |
| 6m | +16.6% | +10.9% |
| 1y | +0.6% | +24.5% |
| ytd | +16.7% | +10.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CL Fundamental Analysis
Colgate-Palmolive's revenue trajectory demonstrates stable, low-single-digit growth, characteristic of a mature consumer staples company. For Q4 2025, revenue was $5.23 billion, representing a 5.78% year-over-year increase. Segment data reveals the Oral, Personal and Home Care segment contributed $4.034 billion (77% of total), while the higher-growth Pet Nutrition segment contributed $1.196 billion (23%). This growth is consistent but modest, reflecting the company's entrenched market position and the defensive, non-cyclical nature of its products. The multi-quarter trend shows revenue has grown from $4.911 billion in Q1 2025 to $5.23 billion in Q4 2025, indicating sequential expansion and resilience. Profitability is robust on an operating basis, but the most recent quarter presented a significant anomaly. The company reported a net loss of -$37 million for Q4 2025, with diluted EPS of -$0.046, which contrasts sharply with net income of $739 million and EPS of $0.90 in Q4 2024. However, this appears to be an isolated event driven by a $970 million 'total other income expenses net' charge, as operating income remained strong at $1.077 billion. Gross margin for the quarter was a healthy 60.15%, and the trailing twelve-month net margin is 10.46%. Excluding the one-time charge, underlying profitability remains solid, with operating margins historically around 21-23%. The balance sheet and cash flow position indicate a highly leveraged but cash-generative business. The debt-to-equity ratio is elevated at 147.93, which is common for large, stable firms in this sector utilizing debt for shareholder returns. The current ratio is 0.995, indicating tight liquidity, but this is typical for efficient working capital management in the industry. Critically, the company generates substantial free cash flow, with TTM free cash flow of $3.634 billion, providing ample coverage for its dividend (payout ratio of 85.5%) and share buybacks. Return on Equity is exceptionally high at 39.48%, though this is magnified by the high financial leverage. The strong and consistent free cash flow underscores the company's ability to service its debt and return capital to shareholders reliably.
Quarterly Revenue
$5.2B
2025-12
Revenue YoY Growth
+0.05%
YoY Comparison
Gross Margin
+0.60%
Latest Quarter
Free Cash Flow
$3.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CL Overvalued?
Given the anomalous net loss in the most recent quarter, we lead with the Price-to-Sales (PS) ratio for valuation, as the trailing PE ratio of 29.97x is distorted by the one-time charge. The trailing PS ratio is 3.14x, and the forward PE (based on estimated EPS) is 22.13x, indicating the market expects a return to normalized profitability. The gap between the trailing PE and forward PE suggests the market is pricing in a recovery from the Q4 net loss and anticipates improved future earnings. Compared to industry averages, Colgate's valuation appears to carry a premium, which is typical for a market leader with strong brands and global diversification. While specific industry average multiples are not provided in the data, consumer defensive staples often trade at a moderate premium due to their predictable cash flows and defensive characteristics. The company's gross margin of 60.1% and operating margin of 21.3% (excluding the Q4 charge) are superior to many peers, potentially justifying a higher multiple. The EV/EBITDA of 17.85x and EV/Sales of 3.77x provide additional context, suggesting the market values its cash-generative enterprise highly. Historically, the stock's own valuation has been volatile, with the trailing PE ratio ranging from extreme negative figures during loss-making quarters to over 40x in recent years. The current trailing PE of 29.97x, while distorted, sits below the highs seen in early 2024 (over 40x) but above the low-20s seen in late 2023. The PS ratio of 3.14x is towards the lower end of its historical range observed in the provided data (which has shown figures from ~12x to over 16x in recent quarters), suggesting the stock may not be excessively valued on a sales basis relative to its own history. This positioning implies the market has not priced in overly optimistic growth expectations, potentially offering a reasonable entry point for a quality defensive name.
PE
30.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -430x~3280x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Colgate faces elevated financial risk from its high debt load, with a debt-to-equity ratio of 147.93. While the substantial TTM free cash flow of $3.63 billion provides coverage, rising interest rates could pressure net income, as seen with $64 million in Q4 interest expense. The Q4 2025 net loss of -$37 million, driven by a $970 million non-operating charge, highlights earnings volatility risk despite strong underlying operations. Furthermore, the current ratio of 0.995 indicates tight liquidity, requiring flawless working capital management to meet short-term obligations.
Market & Competitive Risks: The stock's primary market risk is valuation compression. Trading at a forward P/E of 22.13x, it carries a premium typical for quality staples, but this could contract if investor rotation from value/defensive back to growth accelerates, as hinted at in recent news about a 'rotation trade.' Its significant underperformance versus the S&P 500 (-26.82% over one year) demonstrates this sensitivity. Competitive risks are evergreen in the low-growth consumer staples sector, where market share battles and private label competition can pressure pricing power and margins, though CL's strong brands provide a moat.
Worst-Case Scenario: A severe recession coupled with sustained input cost inflation could compress margins while high debt servicing costs strain cash flow, forcing a dividend cut—a catastrophic event for income-focused investors. This could be exacerbated by a sustained market rotation away from defensive stocks. In this adverse scenario, the stock could re-test its 52-week low of $74.55, representing a potential downside of approximately -17% from the current price of $89.45. The historical max drawdown of -19.66% provides a reasonable estimate of the downside risk in a prolonged bear case.
FAQ
The key risks are: 1) Financial Leverage: A high debt-to-equity ratio of 147.9 increases sensitivity to interest rates. 2) Market Rotation: Persistent underperformance (beta 0.32) means the stock may lag in bull markets, as seen with its -11.3% 3-month relative strength. 3) Earnings Volatility: The Q4 net loss, though from a one-time charge, highlights potential for earnings surprises. 4) Low Growth: As a mature company, revenue growth is limited (~5.8% YoY), capping multiple expansion. The most severe near-term risk is a continued market rotation away from defensive stocks, prolonging its underperformance.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $85 and $95, as it remains range-bound with EPS meeting the analyst average of $4.84. The Bull Case (25% probability) targets $99 to $105, requiring a market shift to defensive stocks and a breakout above the 52-week high. The Bear Case (15% probability) sees a drop to $74-$82, triggered by sustained market rotation away from staples and margin pressure. The most likely outcome is the Base Case, assuming the company executes steadily but fails to attract significant new capital in a growth-oriented market.
CL appears fairly valued. The trailing P/E of 29.97x is distorted by a one-time Q4 charge; the forward P/E of 22.13x is a more relevant metric and is reasonable for a stable, cash-generative market leader. The Price-to-Sales ratio of 3.14x is at the lower end of its recent historical range, suggesting the market is not pricing in excessive growth expectations. Compared to sector peers, CL typically trades at a moderate premium justified by its strong brands and global footprint. The current valuation implies the market expects steady, low-single-digit growth and consistent dividend payments, not a growth breakout.
CL is a good buy for a specific type of investor: those seeking stability, income, and lower portfolio volatility. With a 2.85% dividend yield supported by strong free cash flow and a beta of 0.322, it serves as a defensive anchor. However, for investors seeking growth or market-beating returns, it is less attractive, given its chronic underperformance (-26.8% vs. S&P 500 over one year) and mature, low-single-digit revenue growth. At a forward P/E of 22.1x, the valuation is fair but not a clear bargain. It is a good buy for risk-averse, income-focused portfolios, but not for aggressive growth seekers.
CL is unequivocally a long-term investment. Its low-beta, defensive nature minimizes short-term trading volatility and momentum opportunities. The investment thesis is based on compounding dividend income and capital preservation, not quick capital gains. The stock's chronic underperformance in rallies makes it a poor short-term trade. A minimum holding period of 3-5 years is suggested to collect dividends and potentially benefit from multiple mean reversion during market downturns. Its stability and income profile make it a core holding for retirement or conservative portfolios, not a tactical short-term position.
